The DOI matches its Crossref record; 145 of the 145 references it cites were found in a registry or an index.
Molecular targeted therapies: Ready for “prime time” in biliary tract cancer
Open accessAbstract
Patients with biliary tract cancers (cholangiocarcinoma (CCA) and gallbladder cancer (GBC)) have a poor prognoses and incidence is increasing. Most patients are diagnosed with advanced disease when options of treatment are limited to palliative approaches, mainly focused on chemotherapy. In recent years, novel treatment targets of relevance to biliary tract cancers, mainly present in patients with intrahepatic cholangiocarcinoma (iCCA), have been identified and are rapidly changing the field. These include fibroblast growth factor receptor (FGFR) fusions and isocitrate dehydrogenase (IDH)-1 and -2 mutations which are each present in around 10-20% of patients with iCCA patients. In addition, inhibition of other pathways is currently being explored, such as human epidermal growth factor receptor (HER) family, the Wnt pathway, neurotropic tyrosine kinase receptor (NTRK) fusions and BRAF mutations. The IDH1 inhibitor ivosidenib has already been tested in a phase III clinical trials in pre-treated CCA and showed benefit in terms of progression-free survival (the primary end-point). Multiple FGFR inhibitors are currently in development in phase II and III trials. There has been a consistently high response rate reported for these compounds (ranging between 20.7% and 35.5%), especially for patients harbouring FGFR2 fusions. This review provides an overview of the status of targeted therapies in biliary tract cancers. Detailed discussion regarding current clinical development of IDH and FGFR inhibitors is provided, with an overview of current caveats and future steps.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
Valle, J., Wasan, H., Palmer, D. H., Cunningham, D., Anthoney, A., Maraveyas, A., Madhusudan, S., Iveson, T., Hughes, S., Pereira, S. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908721 · Cited by 4,406
Self-citationMarabelle, A., Le, D. T., Ascierto, P. A., Di Giacomo, A. M., De Jesus-Acosta, A., Delord, J.-P., Geva, R., Gottfried, M., Penel, N., Hansen, A. R., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02105 · Cited by 3,048
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824
Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766
Doebele, R. C., Drilon, A., Paz-Ares, L., Siena, S., Shaw, A. T., Farago, A. F., Blakely, C. M., Seto, T., Cho, B. C., Tosi, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30691-6 · Cited by 1,790
Banales, J. M., Cardinale, V., Carpino, G., Marzioni, M., Andersen, J. B., Invernizzi, P., Lind, G. E., Folseraas, T., Forbes, S. J., Fouassier, L., et al. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.51 · Cited by 1,376
Cholangiocarcinoma: Thirty-one-Year Experience With 564 Patients at a Single Institution
DeOliveira, M. L., Cunningham, S. C., Cameron, J. L., Kamangar, F., Winter, J. M., Lillemoe, K. D., Choti, M. A., Yeo, C. J., & Schulick, R. D. (2007) · Annals of Surgery · doi:10.1097/01.sla.0000251366.62632.d3 · Cited by 1,300
Genomic spectra of biliary tract cancer
Nakamura, H., Arai, Y., Totoki, Y., Shirota, T., Elzawahry, A., Kato, M., Hama, N., Hosoda, F., Urushidate, T., Ohashi, S., et al. (2015) · Nature Genetics · doi:10.1038/ng.3375 · Cited by 1,284
Primrose, J. N., Fox, R. P., Palmer, D. H., Malik, H. Z., Prasad, R., Mirza, D., Anthony, A., Corrie, P., Falk, S., Finch-Jones, M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30915-x · Cited by 1,273
Self-citationAn inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells
Rohle, D., Popovici-Muller, J., Palaskas, N., Turcan, S., Grommes, C., Campos, C., Tsoi, J., Clark, O., Oldrini, B., Komisopoulou, E., et al. (2013) · Science · doi:10.1126/science.1236062 · Cited by 1,153
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
Baselga, J., & Swain, S. M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2656 · Cited by 1,142
Prognostic Nomogram for Intrahepatic Cholangiocarcinoma After Partial Hepatectomy
Wang, Y., Li, J., Xia, Y., Gong, R., Wang, K., Yan, Z., Wan, X., Liu, G., Wu, D., Shi, L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.5984 · Cited by 1,057
Increasing Incidence and Mortality of Primary Intrahepatic Cholangiocarcinoma in the United States
Patel, T. (2001) · Hepatology · doi:10.1053/jhep.2001.25087 · Cited by 1,010
Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma
Jusakul, A., Cutcutache, I., Yong, C. H., Lim, J. Q., Huang, M. N., Padmanabhan, N., Nellore, V., Kongpetch, S., Ng, A. W. T., Ng, L. M., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0368 · Cited by 969
Drilon, A., Siena, S., Ou, S.-H. I., Patel, M., Ahn, M. J., Lee, J., Bauer, T. M., Farago, A. F., Wheler, J. J., Liu, S. V., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1237 · Cited by 826
The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
Helsten, T., Elkin, S., Arthur, E., Tomson, B. N., Carter, J., & Kurzrock, R. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3212 · Cited by 808
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation
Wang, F., Travins, J., DeLaBarre, B., Penard-Lacronique, V., Schalm, S., Hansen, E., Straley, K., Kernytsky, A., Liu, W., Gliser, C., et al. (2013) · Science · doi:10.1126/science.1234769 · Cited by 804
Advances and challenges in targeting FGFR signalling in cancer
Babina, I. S., & Turner, N. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.8 · Cited by 799
HER kinase inhibition in patients with HER2- and HER3-mutant cancers
Hyman, D. M., Piha-Paul, S. A., Won, H., Rodon, J., Saura, C., Shapiro, G. I., Juric, D., Quinn, D. I., Moreno, V., Doger, B., et al. (2018) · Nature · doi:10.1038/nature25475 · Cited by 780
Okusaka, T., Nakachi, K., Fukutomi, A., Mizuno, N., Ohkawa, S., Funakoshi, A., Nagino, M., Kondo, S., Nagaoka, S., Funai, J., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605779 · Cited by 744
Identification of Targetable FGFR Gene Fusions in Diverse Cancers
Wu, Y.-M., Su, F., Kalyana-Sundaram, S., Khazanov, N., Ateeq, B., Cao, X., Lonigro, R. J., Vats, P., Wang, R., Lin, S.-F., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0050 · Cited by 744
Borger, D. R., Tanabe, K. K., Fan, K. C., Lopez, H. U., Fantin, V. R., Straley, K. S., Schenkein, D. P., Hezel, A. F., Ancukiewicz, M., Liebman, H. M., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0386 · Cited by 728
Adjuvant Therapy in the Treatment of Biliary Tract Cancer: A Systematic Review and Meta-Analysis
Horgan, A. M., Amir, E., Walter, T., & Knox, J. J. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.5381 · Cited by 716
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
Javle, M., Lowery, M., Shroff, R. T., Weiss, K. H., Springfeld, C., Borad, M. J., Ramanathan, R. K., Goyal, L., Sadeghi, S., Macarulla, T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.5009 · Cited by 693
Jiao, Y., Pawlik, T. M., Anders, R. A., Selaru, F. M., Streppel, M. M., Lucas, D. J., Niknafs, N., Guthrie, V. B., Maitra, A., Argani, P., et al. (2013) · Nature Genetics · doi:10.1038/ng.2813 · Cited by 684
Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Valle, J. W., Borbath, I., Khan, S. A., Huguet, F., Gruenberger, T., & Arnold, D. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw324 · Cited by 675
Self-citationNew Horizons for Precision Medicine in Biliary Tract Cancers
Valle, J. W., Lamarca, A., Goyal, L., Barriuso, J., & Zhu, A. X. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0245 · Cited by 626
Self-citationIntegrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles
Farshidfar, F., Zheng, S., Gingras, M.-C., Newton, Y., Shih, J., Robertson, A. G., Hinoue, T., Hoadley, K. A., Gibb, E. A., Roszik, J., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.033 · Cited by 610
NTRK gene fusions as novel targets of cancer therapy across multiple tumour types
Amatu, A., Sartore-Bianchi, A., & Siena, S. (2016) · ESMO Open · doi:10.1136/esmoopen-2015-000023 · Cited by 601
Sulkowski, P. L., Corso, C. D., Robinson, N. D., Scanlon, S. E., Purshouse, K. R., Bai, H., Liu, Y., Sundaram, R. K., Hegan, D. C., Fons, N. R., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal2463 · Cited by 555
Arai, Y., Totoki, Y., Hosoda, F., Shirota, T., Hama, N., Nakamura, H., Ojima, H., Furuta, K., Shimada, K., Okusaka, T., et al. (2014) · Hepatology · doi:10.1002/hep.26890 · Cited by 553
Goyal, L., Saha, S. K., Liu, L. Y., Siravegna, G., Leshchiner, I., Ahronian, L. G., Lennerz, J. K., Vu, P., Deshpande, V., Kambadakone, A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1000 · Cited by 552
Edeline, J., Benabdelghani, M., Bertaut, A., Watelet, J., Hammel, P., Joly, J.-P., Boudjema, K., Fartoux, L., Bouhier-Leporrier, K., Jouve, J.-L., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00050 · Cited by 541
Targeting FGFR Signaling in Cancer
Touat, M., Ileana, E., Postel-Vinay, S., André, F., & Soria, J.-C. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2329 · Cited by 524
The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy
Mitri, Z., Constantine, T., & O'Regan, R. (2012) · Chemotherapy Research and Practice · doi:10.1155/2012/743193 · Cited by 519
IDH mutations in cancer and progress toward development of targeted therapeutics
Dang, L., Yen, K., & Attar, E. C. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw013 · Cited by 509
Chan-on, W., Nairismägi, M.-L., Ong, C. K., Lim, W. K., Dima, S., Pairojkul, C., Lim, K. H., McPherson, J. R., Cutcutache, I., Heng, H. L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2806 · Cited by 497
Exome sequencing of liver fluke–associated cholangiocarcinoma
Ong, C. K., Subimerb, C., Pairojkul, C., Wongkham, S., Cutcutache, I., Yu, W., McPherson, J. R., Allen, G. E., Ng, C. C. Y., Wong, B. H., et al. (2012) · Nature Genetics · doi:10.1038/ng.2273 · Cited by 486
Lee, J., Park, S. H., Chang, H.-M., Kim, J. S., Choi, H. J., Lee, M. A., Chang, J. S., Jeung, H. C., Kang, J. H., Lee, H. W., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70301-1 · Cited by 478
Hong, T. S., Wo, J. Y., Yeap, B. Y., Ben-Josef, E., McDonnell, E. I., Blaszkowsky, L. S., Kwak, E. L., Allen, J. N., Clark, J. W., Goyal, L., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.2710 · Cited by 472
Shroff, R. T., Javle, M. M., Xiao, L., Kaseb, A. O., Varadhachary, G. R., Wolff, R. A., Raghav, K. P. S., Iwasaki, M., Masci, P., Ramanathan, R. K., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0270 · Cited by 468
Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials
Eckel, F., & Schmid, R. M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603648 · Cited by 464
Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer
Saha, S. K., Parachoniak, C. A., Ghanta, K. S., Fitamant, J., Ross, K. N., Najem, M. S., Gurumurthy, S., Akbay, E. A., Sia, D., Cornella, H., et al. (2014) · Nature · doi:10.1038/nature13441 · Cited by 460
Ross, J. S., Wang, K., Gay, L., Al-Rohil, R., Rand, J. V., Jones, D. M., Lee, H. J., Sheehan, C. E., Otto, G. A., Palmer, G., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2013-0352 · Cited by 454
Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications
Churi, C. R., Shroff, R., Wang, Y., Rashid, A., Kang, H. C., Weatherly, J., Zuo, M., Zinner, R., Hong, D., Meric-Bernstam, F., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115383 · Cited by 450
Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline
Shroff, R. T., Kennedy, E. B., Bachini, M., Bekaii-Saab, T., Crane, C., Edeline, J., El-Khoueiry, A., Feng, M., Katz, M. H. G., Primrose, J., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02178 · Cited by 445
Self-citationLi, M., Zhang, Z., Li, X., Ye, J., Wu, X., Tan, Z., Liu, C., Shen, B., Wang, X.-A., Wu, W., et al. (2014) · Nature Genetics · doi:10.1038/ng.3030 · Cited by 443
Mutational landscape of intrahepatic cholangiocarcinoma
Zou, S., Li, J., Zhou, H., Frech, C., Jiang, X., Chu, J. S. C., Zhao, X., Li, Y., Li, Q., Wang, H., et al. (2014) · Nature Communications · doi:10.1038/ncomms6696 · Cited by 434
Biliary cancer: Utility of next‐generation sequencing for clinical management
Javle, M., Bekaii‐Saab, T., Jain, A., Wang, Y., Kelley, R. K., Wang, K., Kang, H. C., Catenacci, D., Ali, S., Krishnan, S., et al. (2016) · Cancer · doi:10.1002/cncr.30254 · Cited by 418
Malka, D., Cervera, P., Foulon, S., Trarbach, T., de la Fouchardière, C., Boucher, E., Fartoux, L., Faivre, S., Blanc, J.-F., Viret, F., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70212-8 · Cited by 408
How Fibroblast Growth Factor 23 Works
Liu, S., & Quarles, L. D. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007010068 · Cited by 408
Wang, P., Dong, Q., Zhang, C., Kuan, P.-F., Liu, Y., Jeck, W. R., Andersen, J. B., Jiang, W., Savich, G. L., Tan, T.-X., et al. (2013) · Oncogene · doi:10.1038/onc.2012.315 · Cited by 399
Ebata, T., Hirano, S., Konishi, M., Uesaka, K., Tsuchiya, Y., Ohtsuka, M., Kaneoka, Y., Yamamoto, M., Ambo, Y., Shimizu, Y., et al. (2018) · British Journal of Surgery · doi:10.1002/bjs.10776 · Cited by 397
Tabernero, J., Bahleda, R., Dienstmann, R., Infante, J. R., Mita, A., Italiano, A., Calvo, E., Moreno, V., Adamo, B., Gazzah, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.7341 · Cited by 388
Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968–1998
Taylor-Robinson, S. D., Toledano, M. B., Arora, S., Keegan, T. J., Hargreaves, S., Beck, A., Khan, S. A., Elliott, P., & Thomas, H. C. (2001) · Gut · doi:10.1136/gut.48.6.816 · Cited by 381
IDH mutations in glioma and acute myeloid leukemia
Dang, L., Jin, S., & Su, S. M. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.07.002 · Cited by 370
Mazzaferro, V., El-Rayes, B. F., Droz dit Busset, M., Cotsoglou, C., Harris, W. P., Damjanov, N., Masi, G., Rimassa, L., Personeni, N., Braiteh, F., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0334-0 · Cited by 365
Oncogenic ERBB3 mutations in human cancers.
Jaiswal, B. S., Kljavin, N. M., Stawiski, E. W., Chan, E., Parikh, C., Durinck, S., Chaudhuri, S., Pujara, K., Guillory, J., Edgar, K. A., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.04.012 · Cited by 350
Borad, M. J., Champion, M. D., Egan, J. B., Liang, W. S., Fonseca, R., Bryce, A. H., McCullough, A. E., Barrett, M. T., Hunt, K., Patel, M. D., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004135 · Cited by 344
Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma
Tannapfel, A., Sommerer, F., Benicke, M., Katalinic, A., Uhlmann, D., Witzigmann, H., Hauss, J., & Wittekind, C. (2003) · Gut · doi:10.1136/gut.52.5.706 · Cited by 343
Second-line chemotherapy in advanced biliary cancer: a systematic review
Lamarca, A., Hubner, R. A., David Ryder, W., & Valle, J. W. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu162 · Cited by 339
Self-citationClinical presentation, diagnosis and staging of cholangiocarcinoma
Forner, A., Vidili, G., Rengo, M., Bujanda, L., Ponz‐Sarvisé, M., & Lamarca, A. (2019) · Liver International · doi:10.1111/liv.14086 · Cited by 326
Self-citationFibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma
Graham, R. P., Barr Fritcher, E. G., Pestova, E., Schulz, J., Sitailo, L. A., Vasmatzis, G., Murphy, S. J., McWilliams, R. R., Hart, S. N., Halling, K. C., et al. (2014) · Human Pathology · doi:10.1016/j.humpath.2014.03.014 · Cited by 313
Sia, D., Losic, B., Moeini, A., Cabellos, L., Hao, K., Revill, K., Bonal, D., Miltiadous, O., Zhang, Z., Hoshida, Y., et al. (2015) · Nature Communications · doi:10.1038/ncomms7087 · Cited by 311
Survey of Tyrosine Kinase Signaling Reveals ROS Kinase Fusions in Human Cholangiocarcinoma
Gu, T.-L., Deng, X., Huang, F., Tucker, M., Crosby, K., Rimkunas, V., Wang, Y., Deng, G., Zhu, L., Tan, Z., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0015640 · Cited by 307
Edeline, J., Touchefeu, Y., Guiu, B., Farge, O., Tougeron, D., Baumgaertner, I., Ayav, A., Campillo-Gimenez, B., Beuzit, L., Pracht, M., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.3702 · Cited by 306
Zhu, A. X., Meyerhardt, J. A., Blaszkowsky, L. S., Kambadakone, A. R., Muzikansky, A., Zheng, H., Clark, J. W., Abrams, T. A., Chan, J. A., Enzinger, P. C., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70333-x · Cited by 303
Recent Advances in the Management of Cholangiocarcinomas
Vauthey, J.-N., & Blumgart, L. (1994) · Seminars in Liver Disease · doi:10.1055/s-2007-1007302 · Cited by 298
Chae, Y. K., Ranganath, K., Hammerman, P. S., Vaklavas, C., Mohindra, N., Kalyan, A., Matsangou, M., Costa, R., Carneiro, B., Villaflor, V. M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14109 · Cited by 298
A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer
Ramanathan, R. K., Belani, C. P., Singh, D. A., Tanaka, M., Lenz, H.-J., Yen, Y., Kindler, H. L., Iqbal, S., Longmate, J., Mack, P. C., et al. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-0927-7 · Cited by 284
Valle, J. W., Wasan, H., Lopes, A., Backen, A. C., Palmer, D. H., Morris, K., Duggan, M., Cunningham, D., Anthoney, D. A., Corrie, P., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00139-4 · Cited by 273
Self-citationKim, R. D., Sarker, D., Meyer, T., Yau, T., Macarulla, T., Park, J.-W., Choo, S. P., Hollebecque, A., Sung, M. W., Lim, H.-Y., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0555 · Cited by 262
Bahleda, R., Italiano, A., Hierro, C., Mita, A., Cervantes, A., Chan, N., Awad, M., Calvo, E., Moreno, V., Govindan, R., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3334 · Cited by 246
Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma
Kipp, B. R., Voss, J. S., Kerr, S. E., Barr Fritcher, E. G., Graham, R. P., Zhang, L., Highsmith, W. E., Zhang, J., Roberts, L. R., Gores, G. J., et al. (2012) · Human Pathology · doi:10.1016/j.humpath.2011.12.007 · Cited by 244
Lowery, M. A., Burris, H. A., Janku, F., Shroff, R. T., Cleary, J. M., Azad, N. S., Goyal, L., Maher, E. A., Gore, L., Hollebecque, A., et al. (2019) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30189-x · Cited by 224
Fujimoto, A., Furuta, M., Shiraishi, Y., Gotoh, K., Kawakami, Y., Arihiro, K., Nakamura, T., Ueno, M., Ariizumi, S.-I., Hai Nguyen, H., et al. (2015) · Nature Communications · doi:10.1038/ncomms7120 · Cited by 223
Harding, J. J., Lowery, M. A., Shih, A. H., Schvartzman, J. M., Hou, S., Famulare, C., Patel, M., Roshal, M., Do, R. K., Zehir, A., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0877 · Cited by 223
IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives
de Botton, S., Mondesir, J., Willekens, C., & Touat, M. (2016) · Journal of Blood Medicine · doi:10.2147/jbm.s70716 · Cited by 220
Lamarca, A., Palmer, D. H., Wasan, H. S., Ross, P. J., Ma, Y. T., Arora, A., Falk, S., Gillmore, R., Wadsley, J., Patel, K., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.4003 · Cited by 220
Self-citationNomogram for Predicting the Benefit of Adjuvant Chemoradiotherapy for Resected Gallbladder Cancer
Wang, S. J., Lemieux, A., Kalpathy-Cramer, J., Ord, C. B., Walker, G. V., Fuller, C. D., Kim, J.-S., & Thomas, C. R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.8020 · Cited by 217
Boscoe, A. N., Rolland, C., & Kelley, R. K. (2019) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2019.03.10 · Cited by 210
Galdy, S., Lamarca, A., McNamara, M. G., Hubner, R. A., Cella, C. A., Fazio, N., & Valle, J. W. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9645-x · Cited by 209
Self-citationFibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach
Presta, M., Chiodelli, P., Giacomini, A., Rusnati, M., & Ronca, R. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.05.013 · Cited by 198
Burger, I., Hong, K., Schulick, R., Georgiades, C., Thuluvath, P., Choti, M., Kamel, I., & Geschwind, J.-F. H. (2005) · Journal of Vascular and Interventional Radiology · doi:10.1097/01.rvi.0000143768.60751.78 · Cited by 193
Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study.
Primrose, J. N., Fox, R., Palmer, D. H., Prasad, R., Mirza, D., Anthoney, D. A., Corrie, P., Falk, S., Wasan, H. S., Ross, P. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.4006 · Cited by 190
Self-citationIbrahim, S. M., Mulcahy, M. F., Lewandowski, R. J., Sato, K. T., Ryu, R. K., Masterson, E. J., Newman, S. B., Benson, A., Omary, R. A., & Salem, R. (2008) · Cancer · doi:10.1002/cncr.23818 · Cited by 188
Al-Adra, D. P., Gill, R. S., Axford, S. J., Shi, X., Kneteman, N., & Liau, S.-S. (2015) · European Journal of Surgical Oncology (EJSO) · doi:10.1016/j.ejso.2014.09.007 · Cited by 187
Cholangiocarcinoma With FGFR Genetic Aberrations: A Unique Clinical Phenotype
Jain, A., Borad, M. J., Kelley, R. K., Wang, Y., Abdel-Wahab, R., Meric-Bernstam, F., Baggerly, K. A., Kaseb, A. O., Al-shamsi, H. O., Ahn, D. H., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00080 · Cited by 173
Small Molecule Inhibitors of Bromodomain–Acetyl-lysine Interactions
Brand, M., Measures, A. M., Wilson, B. G., Cortopassi, W. A., Alexander, R., Höss, M., Hewings, D. S., Rooney, T. P. C., Paton, R. S., & Conway, S. J. (2015) · ACS Chemical Biology · doi:10.1021/cb500996u · Cited by 172
Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency
Silva, V. W. K., Askan, G., Daniel, T. D., Lowery, M., Klimstra, D. S., Abou-Alfa, G. K., & Shia, J. (2016) · Chinese Clinical Oncology · doi:10.21037/cco.2016.10.04 · Cited by 169
Wöhrle, S., Bonny, O., Beluch, N., Gaulis, S., Stamm, C., Scheibler, M., Müller, M. M., Kinzel, B., Thuery, A., Brueggen, J., et al. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.478 · Cited by 164
Lamarca, A., Ross, P., Wasan, H. S., Hubner, R. A., McNamara, M. G., Lopes, A., Manoharan, P., Palmer, D., Bridgewater, J., & Valle, J. W. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djz071 · Cited by 162
Self-citationWöhrle, S., Henninger, C., Bonny, O., Thuery, A., Beluch, N., Hynes, N. E., Guagnano, V., Sellers, W. R., Hofmann, F., Kneissel, M., et al. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1810 · Cited by 160
Saha, S. K., Gordan, J. D., Kleinstiver, B. P., Vu, P., Najem, M. S., Yeo, J.-C., Shi, L., Kato, Y., Levin, R. S., Webber, J. T., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1442 · Cited by 160
Porcupine inhibitor suppresses paracrine Wnt-driven growth of Rnf43;Znrf3 -mutant neoplasia
Koo, B.-K., van Es, J. H., van den Born, M., & Clevers, H. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1508113112 · Cited by 158
Chen, J. S., Hsu, C., Chiang, N., Tsai, C. S., Tsou, H., Huang, S.-F., Bai, L., Chang, I. ‐., Shiah, H.-S., Ho, C., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv035 · Cited by 155
Zhu, A. X., Borger, D. R., Kim, Y., Cosgrove, D. C., Ejaz, A. M., Alexandrescu, S. T., Groeschl, R. T., Deshpande, V., Lindberg, J. M., Ferrone, C. R., et al. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3828-x · Cited by 152
Bang, Y., Doi, T., de Braud, F., Piha-Paul, S. A., Hollebecque, A., Razak, A. R. A., Lin, C., Ott, P., He, A. R., Yuan, S., et al. (2015) · European Journal of Cancer · doi:10.1016/s0959-8049(16)30326-4 · Cited by 145
Diagnostic and prognostic biomarkers in cholangiocarcinoma
Macías, R. I. R., Kornek, M., Rodrigues, P. M., Paiva, N. A., Castro, R. E., Urban, S. K., Pereira, S. P., Cadamuro, M., Rupp, C., Loosen, S. H., et al. (2019) · Liver International · doi:10.1111/liv.14090 · Cited by 145
Goyal, L., Govindan, A., Sheth, R. A., Nardi, V., Blaszkowsky, L. S., Faris, J. E., Clark, J. W., Ryan, D. P., Kwak, E. L., Allen, J. N., et al. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0210 · Cited by 142
Leone, F., Marino, D., Cereda, S., Filippi, R., Belli, C., Spadi, R., Nasti, G., Montano, M., Amatu, A., Aprile, G., et al. (2015) · Cancer · doi:10.1002/cncr.29778 · Cited by 142
Byron, S. A., Chen, H., Wortmann, A., Loch, D. C., Gartside, M. G., Dehkhoda, F., Blais, S. P., Neubert, T. A., Mohammadi, M., & Pollock, P. M. (2013) · Neoplasia · doi:10.1593/neo.121106 · Cited by 141
Borger, D. R., Goyal, L., Yau, T., Poon, R. T., Ancukiewicz, M., Deshpande, V., Christiani, D. C., Liebman, H. M., Yang, H., Kim, H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2649 · Cited by 138
Targeting the fibroblast growth factor receptor family in cancer
Hallinan, N., Finn, S. P., Cuffe, S. D., Rafee, S., O'Byrne, K. J., & Gately, K. A. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.03.015 · Cited by 127
Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice
Jain, A., Kwong, L. N., & Javle, M. M. (2016) · Current Treatment Options in Oncology · doi:10.1007/s11864-016-0432-2 · Cited by 126
Gao, Q., Zhao, Y., Wang, X., Guo, W., Gao, S., Wei, L., Shi, J.-Y., Shi, G., Wang, Z., Zhang, Y., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.01.062 · Cited by 125
El-Khoueiry, A. B., Rankin, C. J., Siegel, A. B., Iqbal, S., Gong, I.-Y., Micetich, K. C., Kayaleh, O. R., Lenz, H., & Blanke, C. D. (2014) · British Journal of Cancer · doi:10.1038/bjc.2013.801 · Cited by 123
Anticancer molecules targeting fibroblast growth factor receptors
Liang, G., Liu, Z., Wu, J., Cai, Y., & Li, X. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.07.001 · Cited by 123
Ettrich, T. J., Schwerdel, D., Dolnik, A., Beuter, F., Blätte, T. J., Schmidt, S. A., Stanescu-Siegmund, N., Steinacker, J., Marienfeld, R. B., Kleger, A., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-49860-0 · Cited by 121
Walter, T., Horgan, A. M., McNamara, M. G., McKeever, L., Min, T., Hedley, D. W., Serra, S., Krzyzanowska, M. K., Chen, E. X., MacKay, H. J., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.08.003 · Cited by 119
Self-citationWeiss, A., Adler, F., Buhles, A., Stamm, C., Fairhurst, R. A., Kiffe, M., Sterker, D., Centeleghe, M., Wartmann, M., Kinyamu-Akunda, J., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1291 · Cited by 113
Sakai, D., Kanai, M., Kobayashi, S., Eguchi, H., Baba, H., Seo, S., Taketomi, A., Takayama, T., Yamaue, H., Ishioka, C., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy282 · Cited by 112
Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors
Casadei, C., Dizman, N., Schepisi, G., Cursano, M. C., Basso, U., Santini, D., Pal, S. K., & Giorgi, U. D. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919890285 · Cited by 101
Weekly Gemcitabine for the Treatment of Biliary Tract and Gallbladder Cancer
Tsavaris, N. B., Kosmas, C., Gouveris, P., Gennatas, K., Polyzos, A., Mouratidou, D., Tsipras, H., Margaris, H., Papastratis, G., Tzima, E., et al. (2004) · Investigational New Drugs · doi:10.1023/b:drug.0000011797.09549.53 · Cited by 100
Unruh, D. J., Zewde, M. G., Buss, A., Drumm, M. R., Tran, A. N., Scholtens, D. M., & Horbinski, C. (2019) · Scientific Reports · doi:10.1038/s41598-019-45346-1 · Cited by 100
Ruzzenente, A., Fassan, M., Conci, S., Simbolo, M., Lawlor, R. T., Pedrazzani, C., Capelli, P., D’Onofrio, M., Iacono, C., Scarpa, A., et al. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-5046-6 · Cited by 99
Chae, H., Kim, D., Yoo, C., Kim, K., Jeong, J. H., Chang, H.-M., Lee, S. S., Park, D. H., Song, T. J., Hwang, S., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.07.022 · Cited by 99
Medical treatment for cholangiocarcinoma
Adeva, J., Sangro, B., Salati, M., Edeline, J., Casta, A. L., Bittoni, A., Berardi, R., Bruix, J., & Valle, J. W. (2019) · Liver International · doi:10.1111/liv.14100 · Cited by 98
Self-citationMutational profiling reveals PIK3CA mutations in gallbladder carcinoma
Deshpande, V., Nduaguba, A. M., Zimmerman, S. M., Kehoe, S. M., MacConaill, L. E., Lauwers, G. Y., Ferrone, C. R., Bardeesy, N. M., Zhu, A. X., & Hezel, A. F. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-60 · Cited by 96
Tolcher, A. W., Papadopoulos, K. P., Patnaik, A., Wilson, K. M. O., Thayer, S., Zanghi, J. A., Gemo, A. T., Kavanaugh, W. M., Keer, H. N., & LoRusso, P. M. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv591 · Cited by 94
Fan, B., Mellinghoff, I. K., Wen, P. Y., Lowery, M. A., Goyal, L., Tap, W. D., Pandya, S. S., Manyak, E. L., Jiang, L., Liu, G., et al. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00771-x · Cited by 94
Krook, M. A., Bonneville, R., Chen, H., Reeser, J. W., Wing, M. R., Patacsil, D., Smith, A. M., Dao, T., Samorodnitsky, E., Paruchuri, A., et al. (2019) · Molecular Case Studies · doi:10.1101/mcs.a004002 · Cited by 90
Abou‐Alfa, G. K., Macarulla, T. M., Javle, M. M., Kelley, R. K., Lubner, S. J., Adeva, J., Cleary, J. M., Catenacci, D. V. T., Borad, M. J., Bridgewater, J. A., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz394.027 · Cited by 90
Self-citationBiliary Tract Cancer: State of the Art and potential role of DNA Damage Repair
Lamarca, Á., Barriuso, J., McNamara, M. G., & Valle, J. W. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.09.002 · Cited by 87
Self-citationA Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer
Michael, M., Bang, Y., Park, Y. S., Kang, Y., Kim, T. M., Hamid, O., Thornton, D., Tate, S. C., Raddad, E., & Tie, J. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0502-9 · Cited by 81
Ahn, D. H., Li, J., Wei, L., Doyle, A., Marshall, J. L., Schaaf, L. J., Phelps, M. A., Villalona-Calero, M. A., & Bekaii‐Saab, T. (2015) · Scientific Reports · doi:10.1038/srep12122 · Cited by 80
Loregger, A., Grandl, M., Mejías‐Luque, R., Allgäuer, M., Degenhart, K., Haselmann, V., Oikonomou, C., Hatzis, P., Janssen, K., Nitsche, U., et al. (2015) · Science Signaling · doi:10.1126/scisignal.aac6757 · Cited by 75
Bridgewater, J. A., Lopes, A., Beare, S., Duggan, M., Lee, D., Ricamara, M., McEntee, D., Sukumaran, A., Wasan, H. S., & Valle, J. W. (2016) · BMC Cancer · doi:10.1186/s12885-016-2174-8 · Cited by 75
Self-citationCatenacci, D. V. T., Tesfaye, A. A., Tejani, M. A., Cheung, E. M., Eisenberg, P. D., Scott, A. J., Eng, C., Hnatyszyn, J. H., Marina, N. M., Powers, J. M., et al. (2019) · Future Oncology · doi:10.2217/fon-2019-0141 · Cited by 70
Meric‐Bernstam, F., Arkenau, H., Tran, B., Bahleda, R., Kelley, R. K., Hierro, C., Ahn, D. H., Zhu, A. X., Javle, M. M., Winkler, R. E., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy149 · Cited by 66
HER3, serious partner in crime
Kol, A., van Scheltinga, A. G. T. T., Timmer‐Bosscha, H., Lamberts, L. E., Bensch, F., de Vries, E. G. E., & Schroder, C. P. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.01.005 · Cited by 63
RNF43 interacts with NEDL1 and regulates p53-mediated transcription
Shinada, K., Tsukiyama, T., Sho, T., Okumura, F., Asaka, M., & Hatakeyama, S. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.11.082 · Cited by 62
Javle, M. M., Hainsworth, J. D., Swanton, C., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.4_suppl.402 · Cited by 59
Characterization of FGF401 as a reversible covalent inhibitor of fibroblast growth factor receptor 4
Zhou, Z. M., Chen, X., Fu, Y., Zhang, Y., Dai, S., Li, J., Chen, L., Xu, G., Chen, Z., & Chen, Y. (2019) · Chemical Communications · doi:10.1039/c9cc02052g · Cited by 58
Padmanabhan, V., Steinmetz, H. B., Rizzo, E. J., Erskine, A. J., Fairbank, T. L., Abreu, F. B. D., Tsongalis, G. J., & Tafe, L. J. (2016) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2016-0096-oa · Cited by 49
Kim, S. Y., Kim, S. Y., Ahn, T., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14788 · Cited by 47
New drugs approved for acute myeloid leukaemia in 2018
Küçükyurt, S., & Eşkazan, A. E. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14105 · Cited by 47
2-hydroxyglutarate inhibits MyoD-mediated differentiation by preventing H3K9 demethylation
Schvartzman, J. M., Reuter, V. P., Koche, R. P., & Thompson, C. B. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1817662116 · Cited by 45
Adjuvant Therapy for Intrahepatic Cholangiocarcinoma: The Debate Continues
Zhu, A. X., & Knox, J. J. (2012) · The Oncologist · doi:10.1634/theoncologist.2012-0432 · Cited by 28
The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers
Lamarca, Á., Galdy, S., Barriuso, J., Moghadam, S., Beckett, E., Rogan, J., Backen, A. C., Billington, C., McNamara, M. G., Hubner, R. A., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0206007 · Cited by 26
Self-citationFP-1039 (FGFR1:Fc), a soluble FGFR1 receptor antagonist, inhibits tumor growth and angiogenesis
Zhang, H., Lorianne, M., Baker, K. P., Sadra, A., Bosch, E., Brennan, T., Doberstein, S. K., Goodworth, G., Hestir, K., Hollenbaugh, D. L., et al. (2007) · Molecular Cancer Therapeutics · Cited by 14
Lamarca, Á., Gambardella, V., Cejalvo, J. M., Fleitas, T., & Cervantes, A. M. R. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000547 · Cited by 3
Cited by
Lamarca, A., Palmer, D. H., Wasan, H. S., Ross, P. J., Ma, Y. T., Arora, A., Falk, S., Gillmore, R., Wadsley, J., Patel, K., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00027-9 · Cited by 769
Self-citationJavle, M., Roychowdhury, S., Kelley, R. K., Sadeghi, S., Macarulla, T., Weiss, K. H., Waldschmidt, D.-T., Goyal, L., Borbath, I., El-Khoueiry, A., et al. (2021) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00196-5 · Cited by 428
Dong, L., Lu, D., Chen, R., Lin, Y., Zhu, H., Zhang, Z., Cai, S., Cui, P., Song, G., Rao, D., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2021.12.006 · Cited by 390
Rizzo, A., Ricci, A. D., & Brandi, G. (2021) · Cancers · doi:10.3390/cancers13030558 · Cited by 259
Metadata
- Authors
- Lamarca, A., Barriuso, J., McNamara, M. G., & Valle, J. W.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2020-07
- Volume
- 73
- Issue
- 1
- Pages
- 170-185
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W3010157383
- Cited by
- 367
- References
- 145
- FWCI
- 47.44
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.